John Mascola
Chief Scientific Officer ModeX Therapeutics
Seminars
Thursday 11th September 2025
Beyond Bispecifics: Tetraspecific T Cell Engagers to Enhance T Cell Activation & Overcome Tumor Heterogeneity & Antigen Loss
9:00 am
- A modular tetraspecific antibody platform to maximize the “power of multispecifics” and target complex diseases
- Combining CD3 and CD28 to mimic physiological T cell activation and promote optimal T cells survival and function
- Targeting two tumor antigens with one molecule to address tumor heterogeneity and minimize escape
